Insight Molecular Diagnostics Inc. (IMDX) AI Stock Summary

Snapshot

iMDx is a tiny diagnostics company still pre-commercial scale, with FY 2025 revenue of just $4.1M despite doubling YoY, and a net loss of $50.2M. It burned $25.4M in free cash flow against only $11.6M in cash, leaving under 5 months of runway. Share count more than doubled YoY, and R&D alone ran nearly 4x revenue as it awaits FDA clearance for its flagship test.

What's Happening Right Now

• Mon 10th Aug '26 · Earnings: IMDX reported Q2 2026 results with a net loss of $11.3 million, alongside timely progress on FDA review of its GraftAssureDx kidney-transplant test.
• Fri 7th Aug '26 · Share filing: iMDx filed to register 1.75 million more shares under its equity incentive plan, worth up to about $8.26 million.
• Thu 23rd Jul '26 · Publication: A Lancet Regional Health study highlighted iMDx's GraftAssure assay for guiding kidney transplant drug treatment, alongside confirmed Medicare reimbursement for treatment-response monitoring.
• Thu 16th Jul '26 · Medicare coverage: A new Medicare policy expands coverage and allowed testing frequency for iMDx's dd-cfDNA GraftAssure assay portfolio, supporting commercial adoption.
• Thu 11th Jun '26 · Clinical data: A published study showed iMDx's GraftAssure CM-score outperforming standard tests for detecting kidney transplant rejection, supporting its pending FDA marketing application.

Ownership

Institutions hold 58.5%, insiders hold 1.6%.

Bottom Line

iMDx is a pre-revenue-scale diagnostics story built around FDA approval hopes for its GraftAssureDx test, not a business standing on its own financial feet today. With under 5 months of cash runway, heavy ongoing losses, and share count up over 130% in a year, the company will likely need to raise more money soon, which could dilute existing shareholders further. Positive Medicare coverage news and clinical publications are real progress markers, but they don't change the tight cash picture. A reader should treat this as a high-risk, event-driven story rather than a financially stable business.